SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories - Quaterly Results

13 May 2022 Evaluate
The company's total revenue for the quarter ended March 2022 saw a slight change in the total revenue, having registered a total revenue of Rs. 20063.10 millions.Net profit was down at Rs. 768.80  millions against Rs. 3627.40 millions recorded in the corresponding quarter a year ago.The net profit spiraled down by -78.81%.Operating Profit reported a sharp decline to 2539.20 millions from 4651.80 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 20063.10 19174.70 4.63 88298.10 72196.80 22.30 88298.10 72196.80 22.30
Other Income 542.30 487.70 11.20 1998.90 1900.10 5.20 1998.90 1900.10 5.20
PBIDT 2539.20 4651.80 -45.41 20102.50 21389.40 -6.02 20102.50 21389.40 -6.02
Interest 130.80 73.60 77.72 379.00 429.30 -11.72 379.00 429.30 -11.72
PBDT 2408.40 4450.40 -45.88 19723.50 20832.30 -5.32 19723.50 20832.30 -5.32
Depreciation 550.10 493.80 11.40 2189.80 1989.30 10.08 2189.80 1989.30 10.08
PBT 1858.30 3956.60 -53.03 17533.70 18843.00 -6.95 17533.70 18843.00 -6.95
TAX 1089.50 329.20 230.95 2121.20 1992.20 6.48 2121.20 1992.20 6.48
Deferred Tax 765.40 -380.20 -301.32 -917.00 -1326.10 -30.85 -917.00 -1326.10 -30.85
PAT 768.80 3627.40 -78.81 15412.50 16850.80 -8.54 15412.50 16850.80 -8.54
Equity 239.10 239.10 0.00 239.10 239.10 0.00 239.10 239.10 0.00
PBIDTM(%) 12.66 24.26 -47.83 22.77 29.63 -23.15 22.77 29.63 -23.15

Alkem Laboratories Share Price

5583.70 16.00 (0.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×